Kim Kramer, MD

In my research, I am investigating novel treatments to eliminate microscopic tumor cells in the central nervous system. These novel treatments include monoclonal antibodies attached to radioactive substances (radioimmunotherapy) that are administered directly into the cerebrospinal fluid. We remain one of the few programs in the world committed to the cure of cancers of the leptomeninges.

The use of targeted radioimmunotherapy holds promise because it could reduce our reliance on external-beam radiation therapy to the brain, which can cause developmental delays in some young children. We are exploring new ways to target tumor cells while sparing the central nervous system and the rest of the body from the side effects of radiation.

I am active in teaching residents who are rotating through our service, and have had the special opportunity to mentor several fellows and medical students. I am honored to be part of a subspecialized team of healthcare professionals in Memorial Sloan Kettering’s Department of Pediatrics — including researchers, nurses, nurse practitioners, social workers, and research assistants — who are committed to improving the outcome for our patients.

I am also motivated by the inspirational parents of these patients, who are dedicated to driving legislation that supports funding for and awareness of these cancers. They, too, are vital members of our team. Our ultimate goal is to see our patients come back to see us years from now, doing well and thriving.